XGXue-Min Gao

Xue-Min Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xue-Min Gao has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Li

    Department of Hematology Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

    9 shared publications
  • Lu Zhang

    Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

    6 shared publications
  • Xin-Xin Cao

    Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

    5 shared publications
  • Daobin Zhou

    Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    3 shared publications
  • Hao Cai

    Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    3 shared publications
  • Hao Zhao

    Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

    3 shared publications

Latest Publications

  • Open Access

    Daratumumab plus bortezomib and dexamethasone (Dara‐ VD ) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

    by Gao Xue‐Min, Xu Chengyang, Gao Ya‐Juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐Ni, Li Jian

    Summary: Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a prospective phase 2 trial including 20 stage IIIA and 20 stage IIIB patients. The long‐term follow‐up results are reported here. The 24‐month haematological complete response (CR) and very good partial response (VGPR) rate were 52.5% and 12.5% respectively. Organ responses improved after 12 months; the 24‐month cardiac CR and VGPR rates were 15.0% and 35.0%. After a median follow‐up of 50.9 months, 16 patients died and 10 patients had progressive diseases. The median overall survival (OS) had not been reached in either group, with a 4‐year OS rate of 60.0% (95% confidence interval [CI]: 45.2%–75.2%). The median event‐free survival (EFS) was 33.5 months (95% CI 21.0–46.0 months), with a 4‐year EFS rate of 37.5% (95% CI: 24.3–54.7). No significant difference in OS or EFS was observed between stage IIIA and IIIB patients. In conclusion, the strong anti‐plasma cell regimen Dara‐VD provides comparable long‐term responses and prognosis for Mayo stage IIIB patients.

  • Co-occurrence of Erdheim-Chester disease and clonally evolving acute myeloid leukemia with FLT3-ITD and PTPN11 mutations

    by Xue-Zhu Wang, Xue-Min Gao, Jun-Mei Wang, Hao Cai, Jian Li, Xin-Xin Cao

    Erdheim-Chester disease (ECD) is a rare histiocytosis that tends to co-exist with other myeloid malignancies. Here, we use genetic and transcriptomic sequencing to delineate a case of co-occurring BRAFV600E-mutated ECD and acute myeloid leukemia (AML), followed by AML remission and relapse. The AML relapse involved the extinction of clones with KMT2A-AFDN and FLT3-ITD, and the predominance of PTPN11-mutated subclones with distinct transcriptomic features. This case report has highlighted the screening for other myeloid malignancies at the diagnosis of ECD and the clinical significance of PTPN11-mutated AML subclones that require meticulous monitoring.


  • Open Access

    Long-Term Outcomes of Autologous Stem Cell Transplantation in Patients with Newly Diagnosed POEMS Syndrome

    by An-An Li, Xue-Min Gao, Hao Zhao, Kai-Ni Shen, Lu Zhang, Xin-Xin Cao, Jian Li


  • Open Access

    Functional Subsets of Plasma Cells Associated with Amyloid Production and Venetoclax Sensitivity in Light Chain Amyloidosis

    by Xuezhu Wang, Hongxiao Han, Jian Sun, Qi Wang, Xue-Min Gao, Kai-Ni Shen, Lu Zhang, Yushan Zhao, Xin-Xin Cao, Minping Qian, et al.

    Light-chain amyloidosis (AL) is characterised by a systematic deposition of amyloidogenic immunoglobulin light chains produced by pathogenic bone marrow plasma cells (BMPCs), the features of which remain elusive. Herein, we conducted a single-cell RNA-seq and image flow cytometry analysis of BMPCs in AL in comparison with those in healthy controls and their precursors: monoclonal gammopathy of undetermined significance (MGUS). We identified seven BMPC subsets with overlapping but distinct functions such as DNA repair, cell proliferation, osteoclast differentiation, chromatin organisation, and immunoglobulin production. The subsets enriched in AL overexpressed amyloid-beta binding protein-encoding genes, such as apolipoprotein E (APOE) and cystatin 3 (CST3), and exhibited plasmablastic morphology. The subsets related to aberrant light-chain production in AL upregulated pathways of neutrophil degranulation and transportation to as well as modifications in the Golgi apparatus, especially that of N-linked protein glycosylation. The predominant subset was most susceptible to glucocorticoid and proteasome inhibitors and highly expressed venetoclax sensitivity-associated genes in t(11;14) AL. We further validated a patient subgroup featuring a larger proportion of the predominant subset and a higher expression of cyclin D1 (CCND1) and venetoclax sensitivity-associated genes. Our findings provide insights into the mechanisms underlying the functional heterogeneity of BMPCs in AL.

  • Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis

    by Xin‐Xin Cao, Ming‐Hui Duan, Ai‐Lin Zhao, Hao Cai, Jia Chen, Xue‐Min Gao, Ting Liu, Hua‐Cong Cai, Lu Zhang, Jian Sun, et al.

    Adult Langerhans cell histiocytosis (LCH) remains poorly defined. We retrospectively studied 266 newly diagnosed LCH patients to understand the clinical presentation, treatment, and prognosis of adult LCH. The median age at diagnosis was 32 years (range, 18–79 years). At the time of diagnosis, 40 patients had single lesions within a single system, 18 patients had single pulmonary LCH, 26 patients had multiple lesions within a single system (SS‐m), and 182 patients had multisystem disease (MS). The most common organ involved in MS patients was the bone (69.8%), followed by the pituitary (61.5%) and lung (61.0%). BRAFV600E, BRAF deletion, and MAP2K1 mutation were detected in 38.8%, 25.4%, and 19.4% patients, respectively. BRAF deletion was found more common in patients with MS LCH compared to single‐system LCH (38.5% vs 7.1%, p = .004), also in patients with liver involvement (69.2% vs 14.3%, p < .001). The estimated 3‐year overall survival (OS) and event‐free survival (EFS) rates were 94.4% and 54.7%, respectively, in SS‐m and MS LCH. Multivariate Cox regression showed that involvement of the liver or spleen at baseline predicted poor EFS and receiving cytarabine‐based therapy as a first‐line treatment and age older than 30 years at diagnosis predicted favorable EFS. The involvement of risk organs and age older than 50 years predicted poor OS, and receiving cytarabine‐based therapy predicted favorable OS. Therefore, BRAF deletion was correlated with MS LCH, particularly those with liver involvement. Liver or spleen involvement at baseline indicates a poor prognosis, and a cytarabine‐based regimen could be considered as first‐line treatment for adult LCH patients.


  • Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis

    by Jia Chen, Ai-Lin Zhao, Ming-Hui Duan, Hao Cai, Xue-Min Gao, Ting Liu, Jian Sun, Zhi-Yong Liang, Dao-Bin Zhou, Xin-Xin Cao, et al.


  • Open Access

    Treatment and outcomes of POEMS syndrome: changes in the past 20 years

    by Yan-Ying Yu, Xue-Min Gao, Hao Zhao, Hao Cai, Jun Feng, Lu Zhang, Xin-Xin Cao, Daobin Zhou, Jian Li


  • A highly heterogeneous mutational pattern in POEMS syndrome

    by Jia Chen, Xue-Min Gao, Hao Zhao, Hao Cai, Lu Zhang, Xin-Xin Cao, Dao-Bin Zhou, Jian Li

    POEMS syndrome is a rare plasma cell dyscrasia. Little is known about its pathogenesis and genetic features. We analyzed the mutational features of purified bone marrow plasma cells from 42 patients newly diagnosed with POEMS syndrome using a two-step strategy. Whole exome sequencing of ten patients showed a total of 170 somatic mutations in exonic regions and splicing sites, with paired peripheral blood mononuclear cells as a control. Three significantly mutated genes—LILRB1 (10%), HEATR9 (20%), and FMNL2 (10%)—and eight mutated known driver genes (MYD88, NFKB2, CHD4, SH2B3, POLE, STAT3, CHD3, and CUX1) were identified. Target region sequencing of 77 genes were then analyzed to validate the mutations in an additional 32 patients. A total of 32 mutated genes were identified, and genes recurrently mutated in more than three patients included CUX1 (19%), DNAH5 (16%), USH2A (16%), KMT2D (16%), and RYR1 (12%). Driver genes of multiple myeloma (BIRC3, LRP1B, KDM6A, and ATM) and eleven genes reported in light-chain amyloidosis were also identified in target region sequencing. Notably, VEGFA mutations were detected in one patient. Our study revealed heterogeneous genomic profiles of bone marrow plasma cells in POEMS syndrome, which might share some similarity to that of other plasma cell diseases.


  • Open Access

    Ischemic stroke in patients with POEMS syndrome

    by Jun Feng, Xue-Min Gao, Hao Zhao, Tian-Hua He, Cong-Li Zhang, Kai-Ni Shen, Lu Zhang, Xin-Xin Cao, Ming Qian, Dao-Bin Zhou, et al.

    Polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes (POEMS) syndrome is associated with increased risk for ischemic stroke (IS). Because POEMS syndrome is rare, little is known regarding the underlying mechanism and prognosis for IS in patients in whom it occurs. The medical records of patients with POEMS syndrome were screened between January 2018 and January 2000 at Peking Union Medical College Hospital to identify those with IS. The baseline characteristics, IS features, and patient outcomes were analyzed. Forty-one (8.0%) of 510 POEMS patients were documented to have IS. Patients with IS were older, had a higher percentage of Overall Neuropathy Limitation Scale score >4, and had a higher level of fibrinogen compared with those who did not have IS. Ninety-three percent of IS events occurred before or within 3 months after a diagnosis of POEMS. Of 41 occurrences of IS, 29 (46.3%) were multifocal. Recurrent IS was observed in 13 (31.7%) of 41 patients, but not in patients with successful anti-plasma cell therapy. The 3-year overall survival rate in patients with IS was 71.0% and for those without IS, it was 88.5% (P = .002). We showed that 8.0% of POEMS patients had IS, and most IS events occurred in POEMS patients not being treated effectively. Having IS was a predictor of unfavorable prognosis. Early diagnosis, immediate initiation of treatment for POEMS, and control of POEMS syndrome is key to reducing the occurrence of IS, improving survival, and preventing recurrence of IS.